Objective: To evaluate the clinical outcomes and maternal-neonatal safety of gonadotropin releasing hormone antagonist (GnRH-ant) and gonadotropin releasing hormone agonist (GnRH-a) protocols.
Methods: A total of 2505 women undergoing their first fertilization (IVF)/intracytoplasmic sperm injection (ICSI) were retrospectively analyzed. Patients were divided into GnRH-ant group (n = 1514) and GnRH-a group (n = 991) according their stimulation protocol. Propensity Score Matching (PSM) was used for balancing the baseline of two groups. The pregnancy outcomes were analyzed in fresh transfer cycles, and the obstetric and perinatal outcomes were calculated in singleton live births of fresh cycles. The primary outcome was the live birth rate. The secondary outcome measures were maternal complications, preterm birth rate, low birthweight rate, multiple pregnancy rate, and moderate-severe OHSS rate.
Results: After 1:1 PSM, baseline characteristics of the GnRH-ant group and GnRH-a group were matched and assigned 991 cycles in each group. Before PSM, there were 700 fresh cycles including 237 singleton live births in the GnRH-ant group and 588 fresh cycles including 187 singleton live births in the GnRH-a group. After PSM, there were 471 fresh cycles including 166 singleton live births in the GnRH-ant group and 588 fresh cycles including 187 singleton live births in the GnRH-a group. No significant differences were observed in the live birth rate (44.6% vs 48.8%), maternal complications, preterm birth rate (9.0% vs 6.4%), and low birthweight rate (17.5% vs 24.1%) between two groups after PSM ( > 0.05). The moderate-severe OHSS rate (2.9% vs 6.0%, = 0.002) and multiple pregnancy rate (24.5% vs 33.1%, = 0.025) was significantly lower in the GnRH-ant group than that in the GnRH-a group after PSM.
Conclusion: GnRH-ant protocol was comparable with GnRH-a protocol in clinical outcomes, obstetric and perinatal outcomes, and with a lower risk of OHSS. For those who want to get an effective and safe outcome, and a shorter treatment period, GnRH-ant is a suitable choice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276929 | PMC |
| http://dx.doi.org/10.3389/fendo.2022.875779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating dosage effects of ovulation inhibitors on oocyte maturation in assisted reproductive technology: A retrospective study among patients with normal ovarian reserve.
PLoS One
January 2025
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
The judicious selection of ovulation inhibitors in ovarian stimulation protocols is crucial for the success of assisted reproductive technology (ART). Herein, we investigate the dose-dependent effects of chlormadinone acetate (CMA) and cetrorelix, two distinct ovulation inhibitors, on oocyte maturation in patients with normal ovarian reserve, using univariable and multivariable Poisson regression analyses. Patients undergoing progestin-primed ovarian stimulation (PPOS) with CMA (n = 299) or gonadotropin-releasing hormone antagonist (GnRH-ant) with cetrorelix (n = 605) during their initial in vitro fertilization cycle were enrolled at our center from March 2018 to October 2020 (N = 904).
View Article and Find Full Text PDFGnRH antagonist impairs the process of embryo implantation by inhibiting motility of endometrial stromal cells through reducing c-kit expression.
Gynecol Endocrinol
December 2024
JXHC Key Laboratory of Fertility Preservation, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi Province, China.
Article Synopsis
- The study examines the impact of gonadotropin-releasing hormone antagonist (GnRH-ant) versus agonist (GnRH-a) protocols on clinical outcomes in IVF-ET cycles, involving over 18,000 patients from a specific hospital in China.
- Results indicate patients using GnRH-ant had significantly lower endometrial thickness and poorer outcomes, including lower implantation, pregnancy, and live birth rates, along with a higher rate of early miscarriage compared to the GnRH-a group.
- Additionally, experiments on human endometrial stromal cells revealed that GnRH-ant treatment led to decreased expression of proteins linked to cell migration and adhesion, suggesting these molecular changes may contribute to the observed negative clinical outcomes.
Reproductive outcomes in fresh transfer cycles and antagonists with premature luteinizing and/or progesterone surge: a single center retrospective cohort study.
Front Endocrinol (Lausanne)
October 2024
Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, Shandong, China.
Article Synopsis
- This study looked at how certain hormones affect success rates of getting pregnant when using assisted reproductive technology, which helps people have babies.
- They found that while having a rise in luteinizing hormone didn’t really change the chances of getting pregnant, high levels of progesterone on a specific day were linked to lower chances of having a baby.
- The research showed that if progesterone levels were too high (1.10 ng/ml or more), the chances of having a live birth significantly dropped, so keeping progesterone levels in check is important for better pregnancy outcomes.
Increasing dominant follicular proportion was associated with adverse IVF/ICSI outcomes in low-prognosis women undergoing GnRH antagonist protocol: a retrospective cohort study.
J Ovarian Res
August 2024
Department of Reproductive Medicine, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, 123 Tianfeixiang, Mochou Road, Nanjing, 210004, Jiangsu, China.
Article Synopsis
- The study investigated the link between dominant follicle proportions (DFPs) and IVF/ICSI outcomes for patients in POSEIDON Groups 3 and 4 undergoing GnRH-ant protocols.
- A total of 1,156 patients were analyzed, categorized by DFPs based on the ratio of larger to smaller follicles on the trigger day, and various statistical methods were used to evaluate results.
- Findings revealed that a DFP greater than 40% negatively impacted oocyte retrieval, embryo development, and clinical pregnancy rates in Group 3, suggesting a lower DFP threshold could improve outcomes, whereas Group 4 showed no significant differences in cumulative pregnancy rates between DFP categories.
Effect of LH level on HCG trigger day on clinical outcomes in patients with diminished ovarian reserve undergoing GnRH-antagonist protocol.
Reprod Biol Endocrinol
August 2024
Reproductive Medical Center, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Research Question: Does luteinizing hormone (LH) levels on human chorionic gonadotropin (HCG) trigger day (LH) affect the clinical outcomes of patients with diminished ovarian reserve (DOR) undergoing gonadotropin-releasing hormone antagonist (GnRH-ant) protocol?
Methods: Retrospective analysis fresh embryo transfer cycles of DOR patients who underwent GnRH-ant protocol from August 2019 to June 2023. The participants were divided into different groups according to LH level and age. The clinical data and outcomes were compared between groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!